Source comparison
Mechanism Comparison: Secretagogues vs Exogenous HGH
The critical difference between peptides for HGH alternative and synthetic growth hormone isn't potency. It's how they interact with the body's endogenous regulatory systems. Exogenous HGH administration delivers recombinant human growth hormone (rhGH) directl
This comparison does not assign a generated winner or score.
- The critical difference between peptides for HGH alternative and synthetic growth hormone isn't potency. It's how they interact with the body's endogenous regulatory systems. Exogenous HGH administration delivers recombinant human growth hormone (rhGH) directly into circulation, bypassing the pituitary entirely. Secretagogues stimulate the pituitary to release its own stores and upregulate production.
- When you administer synthetic HGH continuously, serum GH levels remain elevated without the natural peaks and troughs that characterize physiological secretion. This sustained elevation triggers negative feedback through IGF-1, which suppresses endogenous GH production. Within 2–3 weeks of rhGH administration, the pituitary's natural secretory capacity diminishes. Not permanently, but for as long as exogenous hormone is present. This is why HGH protocols require careful cycling and why abrupt discontinuation often produces a rebound suppression period.
- Secretagogues preserve pulsatility. GHRP-induced GH release peaks at 30–60 minutes, returns to baseline by 90–120 minutes, and can be repeated 2–3 times daily without blunting the subsequent pulse. GHRH analogs produce slightly longer elevations (90–180 minutes) but still return to baseline between doses. The pituitary's intrinsic feedback mechanisms remain intact. If IGF-1 rises too high, the next secretagogue dose produces a smaller pulse, preventing the chronic supraphysiological elevation that exogenous HGH creates.
- Research comparing secretagogue protocols to rhGH administration shows comparable IGF-1 increases at equipotent doses, but secretagogues produce lower fasting glucose elevation and less insulin resistance over multi-week protocols. This appears to be downstream of preserved pulsatility. Continuous GH elevation impairs insulin signaling more than intermittent peaks. The practical implication for research: secretagogues allow longer study durations without the metabolic complications that limit exogenous HGH protocols.